证券代码：603439 证券简称：贵州三力 公告编号：2023-037 贵州三力制药股份有限公司 关于2022年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于2023年5月17日以网络远程方式召开2022年度贵州辖区上市公司业绩 说明会暨投资者集体接待日活动，就投资者关心的公司经营业绩、财务状况等事 项与投资者进行了沟通和交流，现将有关事项公告如下： 一、投资者说明会召开情况 本次业绩说明会暨投资者集体接待日活动于2023年5月17日(星期三)下午 15:30-17:30在全景服务平台(网址：http://rs.p5w.net)以网络远程方式召开。关于 本次投资者说明会的召开事项，公司于2023年5月9日在上海证券交易所网站披露 了《贵州三力制药股份有限公司关于参加2022年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告》(2023-034)。 公司董事长、总经理张海先生，公司董事会秘书张千帆先生，公司财务总监 张红玉女士参加了本次投资者说 ...

证券代码：603439 证券简称：贵州三力 公告编号：2023-034 贵州三力制药股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日(星期三)下午 15:30-17:00 会议召开地点：全景服务平台（网址：http://rs.p5w.net） 会议召开方式：网络远程方式 会议问题征集：提问通道自本公告发出之日起开放至2023年5月15日截止， 通过微信关注"贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）于 2023 年 4 月 15 日在上 海证券交易所网站（http://www.sse.com.cn）披露了《公司 2022 年年度报告》。 为加强上市公司与投资者的交流互动，便于投资者进一步了解公司 2022 年度经 营情况及其他关切问题，在贵州证监局指导下，贵州证券 ...

一、业绩说明会的安排 召开时间：2023 年 5 月 17 日 15:30-17:00 召开方式：网络远程方式 证券代码：603439 证券简称：贵州三力 公告编号：2023-034 贵州三力制药股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议问题征集：提问通道自本公告发出之日起开放至2023年5月15日截止， 通过微信关注"贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）于 2023 年 4 月 15 日在上 海证券交易所网站（http://www.sse.com.cn）披露了《公司 2022 年年度报告》。 为加强上市公司与投资者的交流互动，便于投资者进一步了解公司 2022 年度经 营情况及其他关切问题，在贵州证监局指导下，贵州证券业协会联合深圳市全景 网络有限公司举办 2022 年度贵州辖区上市公司业 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥348,977,589.51, representing a year-on-year increase of 119.92%[5] - Net profit attributable to shareholders was ¥54,932,724.23, reflecting a growth of 131.49% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.13, an increase of 116.67% year-on-year[5] - Total revenue for Q1 2023 reached ¥348,977,589.51, a significant increase of 120.3% compared to ¥158,680,694.88 in Q1 2022[19] - Operating profit for Q1 2023 was ¥63,384,620.11, up 160.5% from ¥24,345,225.45 in Q1 2022[20] - Net profit for Q1 2023 amounted to ¥53,396,249.70, representing a growth of 167.0% compared to ¥19,979,984.26 in Q1 2022[20] - Total comprehensive income for the first quarter of 2023 was CNY 54,932,724.23, compared to CNY 23,729,640.91 in the same period of 2022, representing a significant increase[21] - Basic and diluted earnings per share for Q1 2023 were CNY 0.13, up from CNY 0.06 in Q1 2022, indicating a 116.67% increase[21] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥1,889,405,604.26, up 4.01% from the end of the previous year[6] - Total assets as of March 31, 2023, were ¥1,889,405,604.26, an increase from ¥1,816,619,420.45 at the end of 2022[16] - Current assets totaled ¥1,097,464,914.71, down from ¥1,172,058,092.46 at the end of 2022, primarily due to a decrease in cash and cash equivalents[16] - Non-current assets increased to ¥791,940,689.55 from ¥644,561,327.99, driven by growth in intangible assets and goodwill[16] - Total liabilities decreased to ¥528,010,349.39 from ¥578,398,211.98, reflecting a reduction in current liabilities[17] - The company’s equity attributable to shareholders increased to ¥1,295,605,285.33 from ¥1,239,043,767.96, reflecting retained earnings growth[17] Cash Flow - The net cash flow from operating activities was negative at -¥1,351,706.77, a decline of 102.44% year-on-year due to increased expenses related to sales growth[5][8] - Cash inflow from operating activities was CNY 337,896,983.09 in Q1 2023, compared to CNY 221,104,972.51 in Q1 2022, reflecting a growth of 52.93%[23] - Cash outflow from operating activities totaled CNY 339,248,689.86 in Q1 2023, compared to CNY 165,670,243.07 in Q1 2022, resulting in a net cash flow from operating activities of -CNY 1,351,706.77[24] - Cash inflow from investment activities was CNY 64,394,206.67 in Q1 2023, compared to CNY 48,843,199.90 in Q1 2022, marking a 32% increase[24] - Cash outflow from investment activities was CNY 176,471,434.73 in Q1 2023, down from CNY 194,466,733.56 in Q1 2022, indicating a decrease of 9.25%[24] - Net cash flow from investment activities was -CNY 112,077,228.06 in Q1 2023, an improvement from -CNY 145,623,533.66 in Q1 2022[24] - Cash and cash equivalents at the end of Q1 2023 were CNY 455,166,574.82, slightly up from CNY 454,854,470.68 at the end of Q1 2022[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,467[11] Research and Development - The company reported a significant increase in R&D expenses, which rose to ¥5,014,006.28 from ¥1,024,157.45 in Q1 2022, indicating a focus on innovation[20] Other Information - The company did not execute any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[21] - Non-recurring gains and losses totaled ¥1,215,311.30 for the quarter[9] - The company experienced significant growth in product sales, which was the primary driver for the increase in revenue and net profit[8]

证券代码：603439 证券简称：贵州三力 公告编号：2022-024 贵州三力制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 19 日(星期三)至 4 月 23 日(星期日)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zhangqf@gz-sanli. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 4 月 24 日下午 14:00-15:00 举行 2022 年 度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资 ...

Financial Performance - The company reported a total distributable profit of CNY 545,308,475.09 as of December 31, 2022, with a proposed cash dividend of CNY 1.00 per share, totaling CNY 40,986,221.60, which accounts for 20.36% of the net profit attributable to shareholders[6]. - In 2022, the company achieved operating revenue of CNY 1,201,316,448.76, a year-on-year increase of 27.94%[21]. - The net profit attributable to shareholders of the listed company was CNY 201,284,234.02, reflecting a growth of 32.18% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses increased by 43.17% to CNY 194,635,872.55[21]. - The net cash flow from operating activities surged by 89.17% to CNY 293,285,899.02, primarily due to increased cash receipts from sales[21]. - The company's total assets reached CNY 1,816,619,420.45, marking a 29.30% increase from the previous year[21]. - The basic earnings per share rose to CNY 0.49, a 32.43% increase year-on-year[22]. - The weighted average return on equity increased by 2.47 percentage points to 17.74%[22]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7]. - The audit report issued by Dahua Certified Public Accountants confirmed the financial statements' accuracy and completeness, providing a standard unqualified opinion[5]. - The company has implemented a risk control system to enhance operational efficiency and risk management[163]. Product Development and Innovation - The company implemented a "micro-innovation" management initiative, resulting in over 700 proposals and cost savings exceeding CNY 1 million[30]. - The company is focusing on enhancing its product pipeline and brand strategy following the successful restructuring of Dechangxiang, which is expected to contribute positively to future profitability[36]. - The company aims to leverage new policies supporting traditional Chinese medicine to drive innovation and development in the pharmaceutical sector[38]. - The company is developing new products through collaborations with several renowned research institutions, focusing on traditional Chinese medicine modernization[83]. - The company is conducting exploratory new drug development for a proprietary Chinese medicine formula aimed at treating children's purpura[85]. - The company is focusing on the research and development of new products aimed at treating various ailments, including lung heat cough and kidney inflammation[87]. Market Expansion and Sales Strategy - The company expanded its sales team from over 700 to nearly 1,100 by the end of December 2022, enhancing its grassroots market penetration[34]. - The company aims to strengthen its marketing system while expanding its presence in secondary and tertiary terminal channels to improve market share[47]. - The company is actively expanding its OTC sales channels and third terminals to mitigate the impact of price reductions due to national medical reform and strict cost control measures[119]. - The company has expanded its online channels and is exploring the pharmaceutical e-commerce sector, partnering with Alibaba Health Pharmacy and JD Health Pharmacy[114]. Research and Development - Research and development expenses rose to CNY 17,862,876.35, a significant increase of 132.55% compared to the previous year[58]. - The company's R&D investment accounted for 1.49% of operating revenue during the reporting period[94]. - The company invested a total of 1,492.82 million RMB in research and development projects, with a significant increase in the research on the "Ancient Classic Prescription - Qiji Shenkang Granules" by 1,492.82% compared to the previous year[95]. Environmental Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[168]. - The company has committed to not transferring or managing shares held prior to the IPO for 36 months from the listing date[187]. - The company reduced carbon emissions by 158 tons through various technological upgrades in 2022[182]. Corporate Governance - The company held a total of 4 shareholder meetings in 2022, with all resolutions passed successfully[126]. - The total pre-tax remuneration for directors and senior management amounted to 520.63 million CNY in 2022[128]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[160]. Future Outlook - The company plans to continue its strategic initiatives and market expansion efforts in the upcoming year[125]. - The company aims to enhance management efficiency and expand sales channels in 2023, focusing on "micro-innovation" for operational improvements[112]. - The company is committed to ongoing research to ensure the efficacy and safety of its products, particularly in the context of traditional Chinese medicine[88].

Financial Performance - The company's operating revenue for Q3 2022 was ¥280,350,016.75, representing an increase of 18.09% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥39,648,056.50, a decrease of 6.79% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,150,910.59, down 11.54% from the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.09, reflecting a decline of 13.46% compared to the same period last year[10]. - Total operating revenue for Q3 2022 reached ¥710,137,900.69, an increase of 15.6% compared to ¥614,376,129.90 in Q3 2021[25]. - Net profit for Q3 2022 was ¥95,398,331.00, a decrease of 14.1% from ¥110,939,844.61 in Q3 2021[28]. - The net profit attributable to the parent company shareholders for the first three quarters of 2022 is CNY 103,639,947.24, compared to CNY 111,924,172.61 in the same period of 2021, reflecting a decrease of approximately 7.9%[31]. - The basic and diluted earnings per share for the current period are both CNY 0.25, down from CNY 0.27 in the previous year[34]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥1,606,923,327.51, an increase of 21.68% from the end of the previous year[10]. - Total assets as of September 30, 2022, were ¥1,606,923,327.51, compared to ¥1,404,991,334.54 at the end of 2021, indicating a growth of 14.4%[25]. - Total liabilities as of September 30, 2022, amounted to ¥465,730,217.77, an increase from ¥372,926,361.05 at the end of 2021, reflecting a rise of 24.8%[25]. - Shareholders' equity as of September 30, 2022, was ¥1,141,193,109.74, compared to ¥1,032,064,973.49 at the end of 2021, representing an increase of 10.6%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥141,348,018.36, down 5.28% compared to the previous year[10]. - Cash inflows from operating activities totaled CNY 807,693,128.37, an increase from CNY 700,340,919.21 in the same period last year, representing a growth of approximately 15.4%[34]. - Cash outflows from operating activities amounted to CNY 666,345,110.01, compared to CNY 551,115,243.00 in the previous year, showing an increase of about 20.9%[34]. - The net cash flow from operating activities is CNY 141,348,018.36, a decrease from CNY 149,225,676.21 in the same period last year, reflecting a decline of approximately 5.9%[34]. - The net cash flow from investing activities is CNY -172,718,691.54, compared to CNY 6,410,432.53 in the previous year, indicating a significant decline in cash flow from investments[36]. - Cash inflows from financing activities totaled CNY 100,145,623.77, slightly down from CNY 104,920,000.00 in the previous year[36]. - The net cash flow from financing activities is CNY -13,894,382.73, compared to CNY -102,065,833.73 in the previous year, showing an improvement in cash flow management[36]. - The ending cash and cash equivalents balance is CNY 498,953,218.99, down from CNY 503,621,016.75 at the end of the previous year[36]. Operational Insights - The company reported a decrease in operating income due to reduced other income and investment income[12]. - The company has expanded its sales channels, contributing to the increase in operating revenue[12]. - The company has received government subsidies related to specific projects amounting to ¥6,578,211.66 in Q3 2022[10]. - Total operating costs for Q3 2022 were ¥609,551,080.98, up from ¥511,897,328.63 in Q3 2021, reflecting a year-over-year increase of 19.1%[25]. - Research and development expenses in Q3 2022 amounted to ¥11,265,704.67, significantly higher than ¥2,557,036.22 in Q3 2021, indicating a year-over-year increase of 339.5%[28]. - Cash and cash equivalents as of September 30, 2022, were ¥498,953,218.99, down from ¥544,218,274.90 at the end of 2021, representing a decrease of 8.3%[23]. - Accounts receivable increased to ¥292,140,103.48 as of September 30, 2022, compared to ¥256,673,012.56 at the end of 2021, reflecting a growth of 13.8%[23]. - Inventory as of September 30, 2022, was ¥141,189,038.45, up from ¥88,567,082.81 at the end of 2021, marking an increase of 59.4%[23].

Financial Performance - Guizhou Sanli reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[16]. - The company's net profit for the same period was 80 million RMB, up 10% compared to the previous year[16]. - The company's operating revenue for the first half of the year reached ¥429,787,883.94, representing a 14.01% increase compared to ¥376,980,719.84 in the same period last year[24]. - Net profit attributable to shareholders decreased by 7.78% to ¥63,991,890.74 from ¥69,388,454.18 year-on-year[24]. - The net profit after deducting non-recurring gains and losses increased by 8.39% to ¥61,079,477.61 compared to ¥56,352,001.92 in the previous year[24]. - The net cash flow from operating activities was ¥77,357,428.57, down 8.35% from ¥84,403,441.29 in the same period last year[24]. - The company's total assets increased by 9.58% to ¥1,539,590,523.29 from ¥1,404,991,334.54 at the end of the previous year[24]. - Basic earnings per share decreased by 5.88% to ¥0.16 from ¥0.17 year-on-year[24]. - The weighted average return on net assets decreased by 0.94 percentage points to 6.00% from 6.94% in the previous year[24]. - The company reported a total of 14,403,914.98 million yuan in revenue for the first half of 2022, reflecting a growth compared to the previous period[67]. Market Expansion and Product Development - User data indicates a growth in customer base by 20%, reaching 1 million active users[16]. - The company plans to launch three new products in the second half of 2022, focusing on herbal medicine and OTC drugs[16]. - Guizhou Sanli aims to expand its market presence in Southeast Asia, targeting a 25% increase in international sales by the end of 2023[16]. - The company is focusing on expanding its core product line and exploring new products as part of its "14th Five-Year Plan" strategy[46]. - The company’s core product, the Kaohoujian spray (children's type), has covered 323 cities and 1,856 counties, reaching over 152,000 various terminals, including more than 5,000 grade hospitals and over 104,000 retail terminals[40]. Research and Development - The company has allocated 50 million RMB for R&D in new technologies and product development[16]. - Research and development expenses surged by 419.92% to approximately ¥2.46 million, compared to ¥473,240.09, reflecting increased investment in R&D[53]. - The company has established long-term strategic partnerships with multiple research institutions and universities to enhance product quality and safety[38]. Quality Control and Production Management - The company has established a comprehensive quality control system in accordance with the new GMP certification, ensuring strict adherence to production quality management standards[34]. - The company emphasizes continuous quality checks during production, including self-inspection, mutual inspection, and specialized inspections by the quality assurance department[34]. - The company has implemented a standardized production process with specific technical standards and operational procedures to enhance production management[34]. - The company has a dual supplier strategy for raw materials to ensure stable supply and mitigate risks[34]. Financial Management and Investments - The company completed the bankruptcy reorganization of its subsidiary, Dechangxiang, in May 2022, integrating it into the consolidated financial statements[51]. - The company proposed over 300 process optimizations through its "micro-innovation" initiative, resulting in cost savings of over ¥400,000[48]. - The company has increased its external equity investment by RMB 240.48 million compared to the previous year[61]. - The company reported a net investment income of CNY 7,220,817.91, a decrease from CNY 16,293,342.25 in the previous year, indicating a decline of approximately 55.7%[163]. Environmental Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[81]. - The company operates two natural gas boilers, which are equipped with dust capture and exhaust gas absorption devices, ensuring emissions meet national standards[81]. - The company has received environmental impact assessment approvals for multiple production lines, including a 60 million bottle spray production line and a 500 million capsule production line, both in normal production[84]. - The company actively responds to national carbon neutrality initiatives by using energy-saving equipment and clean energy such as natural gas, aiming to reduce carbon emissions[97]. Shareholder and Corporate Governance - The company held its annual shareholders' meeting on May 19, 2022, where all proposals were approved[74]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing[100]. - The company will ensure compliance with regulations regarding related party transactions to protect shareholder interests[114]. - The largest shareholder, Zhang Hai, holds 188,668,440 shares, representing 45.92% of the total shares, with 70,000,000 shares pledged[137].

证券代码：603439 证券简称：贵州三力 编号：2022-035 贵州三力制药股份有限公司 关于"2021年度业绩说明会暨投资者集体接待日活动" 举办情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）于2022年5月13日参加了 贵州证监局、贵州证券业协会联合深圳市全景网络有限公司举办的2021年度业绩 说明会暨投资者集体接待日活动（以下简称"活动"），就投资者关心的公司经 营业绩、财务状况、发展战略规划等事项与投资者进行了沟通和交流，现将有关 事项公告如下： 一、本次活动举办情况 本次活动于2022年5月13日09:30-11:30在"全景路演"(http://rs.p5w.net) 举办。关于本次活动的举办事项，公司于2022年5月6日在上海证券交易所网站披 露了《贵州三力制药股份有限公司关于举办"2021年度业绩说明会暨投资者集体 接待日活动"的公告》(2022-030)。 公司董事长、总经理张海先生，公司董事、董事会秘书张千帆先生，公司董 事、财务总监张红玉女士参 ...

证券代码：603439 证券简称：贵州三力 公告编号：2022-030 贵州三力制药股份有限公司 关于举办"2021年度业绩说明会暨投资者集体接待日 活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，贵州证监局、贵州证券业 协会联合深圳市全景网络有限公司，将于 2022 年 5 月 13 日 09:30-11:30 在"全 景路演"(http://rs.p5w.net)举办"2021 年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动"。 出席本次活动人员有: 公司董事长暨总经理张海先生、董事会秘书张千帆先 生、财务总监张红玉女士。 为充分尊重投资者、提升交流的针对性,现就公司本次活动提前向投资者公 开征集问题 , 广 泛 听 取 投 资 者 的 意 见 和 建 议 。 投 资 者 可 即 日 起 访 问 https://ir.p5w.net/zj/，进入问题征集专题页面提交问题。公司将在会 ...